ArthroCare closes Opus merger:
This article was originally published in Clinica
Executive Summary
ArthroCare, the Sunnyvale, California-based developer of Coblation technology, has completed its acquisition of Opus Medical. ArthroCare first announced its intention to buy the orthopaedic soft tissue repair systems developer in September (see Clinica No 1123, p 14) and has paid $30m in cash and $60m of ArthroCare stock up front. Further delayed and contingent payments will be made in 2005 and 2006.
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.